Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cancer Genet ; 284-285: 5-11, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38471404

ABSTRACT

Systemic mastocytosis (SM) is a myeloproliferative neoplasm displaying abnormal mast cell proliferation. It is subdivided into different forms, including aggressive systemic mastocytosis (ASM) and systemic mastocytosis with an associated hematologic neoplasm (SM-AHN). Oncogenic genetic alterations include point mutations, mainly the KIT D816V, conferring poor prognosis and therapy resistance, and fusion genes, with those involving PDGFRA/PDGFRB as the most recurrent events. We here describe an ASM case negative to the KIT D816V and JAK2 V617F alterations but showing a RUNX1 frameshift heterozygous mutation and the co-occurrence of three fusion transcripts. The first one, PRKG2::PDGFRB, was generated by a balanced t(4;5)(q24;q32) translocation as the sole abnormality. Other two novel chimeras, KAT6A::NCOA2 and RXRA::NOTCH1, originated from cryptic intra-chromosomal abnormalities. The patient rapidly evolved towards SM-AHN, characterized by the persistence of the PRKG2::PDGFRB chimera, due to the presence of an extra copy of the der(5)t(4;5)(q24;q34) chromosome and an increase in the RUNX1 mutation allelic frequency. The results indicated that the transcriptional landscape and the mutational profile of SM deserve attention to predict the evolution and prognosis of this complex disease, whose classification criteria are still a matter of debate.


Subject(s)
Core Binding Factor Alpha 2 Subunit , Frameshift Mutation , Mastocytosis, Systemic , Oncogene Proteins, Fusion , Humans , Core Binding Factor Alpha 2 Subunit/genetics , Mastocytosis, Systemic/genetics , Oncogene Proteins, Fusion/genetics , Receptor, Notch1/genetics , Nuclear Receptor Coactivator 2/genetics , Male , Heterozygote , Female , Middle Aged , Histone Acetyltransferases
2.
Ann Rheum Dis ; 69(2): 424-7, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19740900

ABSTRACT

OBJECTIVE: To determine the incremental cost-effectiveness ratios (ICERs) of two therapeutic regimens of infliximab for ankylosing spondylitis (AS). METHODS: 230 patients with active AS who were participating in a randomised controlled trial comparing two infliximab infusion modalities-every 6 weeks (Q6) and on demand (DEM)-were included in an economic evaluation within the trial. Data were collected by phone every 3 months for 1 year. Direct and indirect costs were calculated from a payer perspective. Health-related quality of life was assessed with a general health rating scale. ICERs were calculated for one 20% improvement (ASAS20), for one partial remission and for one quality-adjusted life year (QALY) gained. RESULTS: The Q6 regimen was significantly more efficacious than the DEM regimen but also more costly (euro22 388 vs euro17 596; p<0.001), because it required significantly more infliximab infusions per patient (8.4 vs 6.2). The ICERs of the Q6 to DEM regimen were euro15 841 for one ASAS20 response, euro23 296 for one partial remission and euro50 760 for one QALY gained. CONCLUSION: The administration of infliximab every 6 weeks is cost effective as compared with a DEM regimen; however, the ICER is close to the acceptability threshold of euro50 000 for one QALY gained. TRIAL REGISTRATION NUMBER: NCT 00439283.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antirheumatic Agents/administration & dosage , Spondylitis, Ankylosing/drug therapy , Adult , Antibodies, Monoclonal/economics , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/economics , Antirheumatic Agents/therapeutic use , Cost of Illness , Cost-Benefit Analysis , Drug Administration Schedule , Drug Costs/statistics & numerical data , Female , Humans , Infliximab , Male , Middle Aged , Quality of Life , Severity of Illness Index , Spondylitis, Ankylosing/economics , Tumor Necrosis Factor-alpha/antagonists & inhibitors
3.
Ann Oncol ; 17(5): 794-800, 2006 May.
Article in English | MEDLINE | ID: mdl-16497823

ABSTRACT

OBJECTIVE: To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients. PATIENTS: Between 1997 and 2004, 26 new cases of NK/T-cell lymphoma 'nasal type' were diagnosed in 10 Italian Hematology institutions. RESULTS: All patients were Caucasian, male/female ratio was 19/7, with a median age of 50 years (range 20-80). In 23 cases presentation at the onset was in the nasal cavity or adjacent structures, in two cases the lymphoma onset with skin lesions was followed successively by rhynopharyngeal dissemination, while the remaining case had bone marrow and lymph node involvement followed by oro-pharyngeal involvement. Regarding the stage of disease: 12 patients were in stage I; six in stage II; eight in stage IV. Diagnosis was based on the finding of a NK/T-cell phenotype at the histological and immunophenotypic examination of oropharyngeal or cutaneous lesions. All patients but one were treated with chemotherapy, alone in nine cases or associated to radiotherapy in 14 cases; two patients had chemotherapy, radiotherapy and surgery, while one patient underwent only surgery. Chemotherapy was anthracycline-based in 17 out of 25 cases. In those patients in whom radiotherapy was performed, radiation dosages ranged between 36 Gy and 47.5 Gy, with a median dosage of 40 Gy. Nine patients (34%) were responsive to the treatments: six patients obtained a complete remission and other three a partial remission. The remaining 17 patients resulted refractory or presented a limited response to therapy. The median disease-free survival was 14 months and the median overall survival time was 9 months. CONCLUSION: The results of this retrospective survey confirmed that NK/T-cell lymphoma 'nasal type' is a very rare lymphoma in the Italian population, and it is characterized by a very bad prognosis. Due to the rarity of this disease, a standardized therapeutic approach is lacking. More data are needed to know the epidemiology of this kind of lymphoma in Europe.


Subject(s)
Killer Cells, Natural/pathology , Lymphoma, T-Cell/pathology , Nasal Cavity/pathology , Neoplasm Staging , Nose Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Female , Health Surveys , Humans , Male , Middle Aged , Nose Neoplasms/therapy , Prognosis , Radiotherapy Dosage , Retrospective Studies , Survival Rate
4.
Ann Rheum Dis ; 64(11): 1647-9, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16227416

ABSTRACT

OBJECTIVES: To assess the incidence of infusion reactions in patients with rheumatoid arthritis (RA) receiving infliximab treatment with and without betamethasone premedication. To determine whether patients with an atopic diathesis had a better response to corticosteroid pretreatment than those without, and the course of patients' functional capacity and quality of life. PATIENTS AND METHODS: A prospective, multicentre, randomised, double blind phase 4 study of 355 patients with RA in two groups: group A received betamethasone and group B placebo, before a 36 week infusion treatment with infliximab. Incidence and severity of infusion reactions from infliximab treatment were assessed. RESULTS: The incidence of reactions to infliximab infusion was <5%. More infusion reactions occurred with betamethasone pretreatment than with placebo. Response to infliximab of patients with atopic backgrounds did not differ in the presence or absence of betamethasone from that of non-atopic patients. Mean Health Assessment Questionnaire score improved by 47% at week 24, quality of life assessed by Short Form-36 improved in mental and physical component subscales. CONCLUSIONS: Incidence of infusion reactions with infliximab was low and their severity generally mild, but betamethasone pretreatment did not decrease the incidence and severity of infusion reactions. Betamethasone, therefore, is not recommended as a systematic prophylactic measure, even in atopic patients.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Betamethasone/therapeutic use , Adult , Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/pathology , Double-Blind Method , Drug Therapy, Combination , Female , Health Status Indicators , Humans , Infliximab , Infusions, Intravenous , Male , Middle Aged , Prospective Studies , Quality of Life , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors
5.
Mycoses ; 47(3-4): 163-7, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15078435

ABSTRACT

In this paper we analysed clinical, laboratory characteristics and outcome of patients with haematological diseases who developed an Aspergillus niger infection, in a multicentre study involving 14 Italian Haematological Divisions during a 10-year period. The study recorded 194 consecutive microbiologically documented aspergilloses, eight of which (4%) were due to A. niger, and were observed only in five of the participating centres. The primary localization of infection was lung in seven cases and paranasal sinus in one case. Seven patients died at the end of follow-up. The death was mainly attributable to A. niger progression in six of them. Our study that collected the largest number of cases of A. niger infection in haematological malignancies confirms that this infrequent complication is characterized by a high mortality rate.


Subject(s)
Anemia, Aplastic/complications , Aspergillosis , Aspergillus niger , Leukemia/complications , Lung Diseases, Fungal , Lymphoma/complications , Adult , Aged , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/microbiology , Aspergillosis/mortality , Aspergillus niger/drug effects , Aspergillus niger/isolation & purification , Bronchoalveolar Lavage Fluid/microbiology , Fatal Outcome , Female , Humans , Leukemia/drug therapy , Lung Diseases, Fungal/microbiology , Lymphoma/drug therapy , Male , Middle Aged , Retrospective Studies , Sputum/microbiology , Treatment Outcome
6.
Bone Marrow Transplant ; 28(4): 365-7, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11571508

ABSTRACT

In the bone marrow transplant setting, several authors hypothesized that severely overweight patients are at increased risk of transplant-related toxicity, but different definitions of obesity, different body weight groupings and heterogeneous samples of patients were analyzed. To overcome these limitations, we retrospectively considered a homogeneous group of 54 patients (median age 36.5 years), with a diagnosis of de novo acute myeloid leukemia (AML), autografted in first complete remission (CR) with the Bu-Cy2 conditioning regimen, dosed on actual body weight. Patients were classified into three groups (obese, non-obese, underweight) using body mass index (BMI = kg/m(2)); for each group we analyzed transplant-related toxicity and mortality, overall survival and disease-free survival (OS/DFS). In spite of the relatively small number of patients, in our results high BMI appears a predictive factor for an increase of treatment-related toxicity and mortality. Moreover, 30 (55%) patients are currently alive in continuous CR, and after a median follow-up of 76.5 months (range 14-137) statistically significant differences in OS and DFS were detected between obese and non-obese groups (P = 0.012 and 0.021, respectively). Our study suggests that obesity may represent an independent risk factor for autograft in AML and further investigations are warranted.


Subject(s)
Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/physiopathology , Leukemia, Myeloid, Acute/therapy , Obesity/physiopathology , Adult , Body Mass Index , Body Weight , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Humans , Male , Middle Aged , Obesity/mortality , Retrospective Studies , Survival Rate , Transplantation Conditioning/adverse effects , Transplantation Conditioning/mortality , Transplantation, Autologous
7.
Fundam Clin Pharmacol ; 15(2): 151-6, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11468025

ABSTRACT

A randomized multicenter study in intensive care unit (ICU) patients, evaluated the capacity of a Bayesian method to obtain an optimal first isepamicin (ISP) peak of 80 mg/L in comparison to a fixed loading dose (LD). Patients (n=236) over 18 years of age were enrolled from 6 September 1997 to 17 July 1999 and randomly assigned to received ISP in a calculated dose (CD) or a loading dose (LD) of 25 mg/kg body weight. The CD was estimated using a specific population model with Bayesian methodology implemented in the PKS program (Abbott PKS, Abbott Diagnostics, Rungis, France). The data required included age, body weight, height, gender and serum creatinine. ISP disposition is described by a one-compartment model. Blood samples were drawn 1 and 24 h after the start of infusion for fluorescence polarization immunoassay measurement of serum ISP concentrations. The predictive performance was assessed by computing bias and precision. Peak concentrations were significantly higher in CD group than the LD group (84.2 +/- 28.6 vs. 74.7 +/- 24.1 mg/L, respectively; P=0.008), but trough levels were comparable. The optimal ISP peak was attained by a significantly higher percentage of CD patients (P=0.018), and by significantly more CD patients on mechanical ventilation (P=0.025), and with simplified acute physiological scores (SAPS) > 35 (P=0.002). Pharmacokinetic parameters were similar for the two groups with large interindividual variations. Mean (+/- SD) volume of distribution of ventilated patients (72%) was significantly higher than of nonventilated patients (23.31 +/- 7.35 vs. 20.60 +/- 6.30 L, respectively; P=0.001). No relationship was found between the volume of distribution and SAPS. Total clearance was significantly correlated with estimated CLCR (creatinine clearance) (P=0.0001). Precision (RMSE) is better for CD than for LD strategy, respectively 27.96 and 28.66 mg/L. The Bayesian method was significantly more accurate and performed particularly well in ventilated patients and patients with high SAPS, compare to an LD of 25 mg/kg to obtain a first ISP peak of 80 mg/L in ICU patients. Therefore, a fixed dose of 28.5 mg/kg would be also adequate to reach a peak of 80 mg/L.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Critical Care , Gentamicins/pharmacokinetics , Acute Disease , Adult , Aged , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Bayes Theorem , Creatinine/metabolism , Female , Gentamicins/administration & dosage , Gentamicins/blood , Gentamicins/therapeutic use , Humans , Infusions, Intravenous , Intensive Care Units , Linear Models , Male , Metabolic Clearance Rate , Middle Aged , Respiration, Artificial , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...